Genmab Operating Income 2019-2022 | GMAB

Genmab annual/quarterly operating income history and growth rate from 2019 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Genmab operating income for the quarter ending March 31, 2022 was $0.078B, a 10.12% decline year-over-year.
  • Genmab operating income for the twelve months ending March 31, 2022 was $0.471B, a 54.8% decline year-over-year.
  • Genmab annual operating income for 2021 was $0.48B, a 50.35% decline from 2020.
  • Genmab annual operating income for 2020 was $0.967B, a 144.58% increase from 2019.
  • Genmab annual operating income for 2019 was $0.395B, a 80.86% increase from 2018.
Genmab Annual Operating Income
(Millions of US $)
2021 $480
2020 $967
2019 $395
2018 $219
Genmab Quarterly Operating Income
(Millions of US $)
2022-03-31 $78
2021-12-31 $125
2021-09-30 $141
2021-06-30 $128
2021-03-31 $86
2020-12-31 $158
2020-09-30 $135
2020-06-30 $664
2020-03-31 $10
2019-12-31 $443
2019-09-30 $52
2019-06-30 $21
2019-03-31 $90
2018-12-31 $196
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $20.430B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00